scispace - formally typeset
J

Javier Rejas

Researcher at Pfizer

Publications -  204
Citations -  5156

Javier Rejas is an academic researcher from Pfizer. The author has contributed to research in topics: Pregabalin & Neuropathic pain. The author has an hindex of 36, co-authored 202 publications receiving 4501 citations.

Papers
More filters
Journal ArticleDOI

Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool

TL;DR: The cultural adaptation into Spanish of the 7-item self-administered GAD-7 scale, which is used to identify probable patients with GAD, was carried out and the validity of its content and the relevance and adequacy of items in the Spanish cultural context were confirmed.
Journal ArticleDOI

Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.

TL;DR: The prevalence of negative symptoms in patients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice not only is still considerably high but also seems to be related to poorer functioning, unemployment, greater severity, and less positive symptomatology and higher antipsychotic dose.
Journal ArticleDOI

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

TL;DR: CHD risk and MS prevalences among patients with schizophrenia treated with antipsychotics were in the same range as the Spanish general population 10 to 15 years older.
Journal ArticleDOI

Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care

TL;DR: The GAD-7 scale has been shown to highly correlate not only with specific anxiety but also with disability measures, and this instrument could be a good choice to explore the level of patient disability in subjects with GAD in primary care settings.
Journal ArticleDOI

Frequency of Sexual Dysfunction and Other Reproductive Side-effects in Patients with Schizophrenia Treated with Risperidone, Olanzapine, Quetiapine, or Haloperidol: The Results of the EIRE Study

TL;DR: The results suggest that none of the atypical antipsychotics that were studied significantly improved sexual dysfunction and other reproductive side-effects of the conventional antipsychotic, haloperidol, in stabilized patients during long-term treatment.